Star Health and Allied Insurance (STAHEA)



CMP: ₹740

Target: ₹ 860(16%)

Target Period: 12 months July 31, 2022

Leadership in retail health continues, Outlook steady

About the stock: Star Health is the largest standalone insurer engaged in health insurance segment with relatively superior market share, operating performance.

- Star Health is a market leader in the retail health insurance segment with ~31.6% market share, as of June 2022
- Star Health has 807 branches and 13000+ network hospitals, with a presence in 25 states and five union territories

Q1FY23 Results: Lower claims aids profitability

- GWP up 13% YoY to ₹2463 crore, NWP up 32.6% YoY and NEP up 20% YoY
- Incurred claims decline 12.8% YoY to ₹ 1781 crore, Claims ratio down from 91.0% to 66.3% as impact of Covid recedes
- Underwriting profit at ₹156.8 crore versus a loss of ₹416 crore YoY
- Combined ratio (as reported) at 98.2% versus 121.1% YoY
- Net profit stood at ₹213.2 crore versus a loss of ₹209.8 crore YoY

What should investors do? Star Health is expected to maintain its leadership in retail health segment with sustainable long term growth opportunity. Steady claims ratio and 20-25% growth in premium to improve combined ratio and support RoE.

We maintain a BUY rating on the stock

Target Price and Valuation: We value Star Health at ~3.1x FY24E GDPI (59x FY24E EPS) to arrive at revised TP of ₹860 from ₹825 earlier.

Key triggers for future price performance:

- Under penetration & lower density provides long term growth opportunity
- Improving footprints in rural India & launch of specialised products to help maintain above industry growth and thus maintain market leadership
- Prospect of increase in number of banc-assurance partners along with strengthening of own agency channel to propel business momentum
- Life insurance selling health indemnity to increase competition, though fear seems overdone at this time

Alternate Stock Idea: Apart from Star Health, we like HDFC Life Insurance.

- It is among the most dominant players in the Indian life insurance industry
- BUY with target price of ₹635

Key Financial Summary							
	FY20	FY21	FY22	3 year CAGR (FY19-FY22)	FY23E	FY24E	2 year CAGR (FY22-FY24E)
Gross written premium (GWP)	6890.7	9388.5	11739.6	29.4	14356.8	17664.0	22.7
Net Incurred Claims	3087.4	4369.5	8727.5	56.0	8239.9	9946.7	6.8
Underwriting Profit/Loss	168.4	(1331.8)	(2127.2)	NA	326.1	395.9	NA
Profit after Tax	272.0	(825.6)	(1203.6)	NA	705.4	832.2	NA
NWP/Net Worth (x)	3.2	1.7	1.8		2.1	2.6	
Price/Float (x)	1.0	0.6	0.4		0.4	0.3	
P/GWP (x)	0.6	0.5	0.4		0.3	0.2	
P/E (x)	160.2	(52.8)	(36.2)		62.1	52.6	

Source: Company, ICICI Direct Research


Health Insurance

BUY

Particulars	
Particulars	Amount
Market Capitalisation	₹ 42784 crore
52 week H/L	940/469
Net Worth	₹ 4881 crore
Face Value	₹10

Shareholdi	ng Pattern		
(in %)	Dec-21	Mar-22	Jun-22
Promoter	58.9	58.9	58.8
FII	9.9	9.8	9.6
DII	27.4	27.3	27.2
Others	3.75	4.02	4.34

Price performance



Key Highlights

Claims ratio down to 98.2% to 121.1% YoY

Key risk: i) Increasing competition could limit pricing power ii) rising yields could limit investment income

Research Analyst

Vishal Narnolia vishal.Narnolia@icicisecurities.com

Kajal Gandhi Kajal.Gandhi@icicisecurities.com

Sameer Sawant sameer.sawant@icicisecurities.com

Pravin Mule Pravin.mule@icicisecurities.com

Initiating Coverage

Key takeaways of recent quarter & conference call highlights

Q1FY23 Results: Modest quarter on overall business growth

- Gross written premium (GWP) was up by 12.7% YoY (down 33% QoQ due to seasonality) to ₹2463 crore. This growth was slower than total industry growth of 22.5% and SAHI player's growth of 27.9% (according to provisional data from general insurance council).
- Net written premium (NWP) was up by 14.4% YoY while earned premium growth was higher at 19.8% YoY to ₹2687 crore, indicating higher flow from previously written policies.
- Retail health segment GDPI growth was at 20.2% YoY and this segment formed 93.4% of total GDPI premium. Market share in retail health segment stood at 31.6% as against 29.2% YoY.
- Incurred claims declined by 12.8% to ₹1781 crore, mostly due to waning impact of 3rd wave of pandemic. Thus, claims ratio came in at 66.28% in Q1FY23 vs 68.09% in Q4FY22 & 91.01% YoY.
- Combined ratio came in at 98.2% vs 121.4% YoY and insurer posted an underwriting profit of ₹156.8 crore. With an investment income (policyholder) of ₹122 crore, operating profit of ₹278.8 crore.
- Total float was up 38% YoY to ₹11462 crore and investment income (shareholder + policyholders) came in at ₹204 crore, up 41% YoY. Thus, Star Health posted a net profit of ₹213 crore, versus a loss of ₹209 crore YoY and against our expectation of a profit of ₹142 crore.

Q1FY23 Earnings Conference Call highlights

- Retail Health growth moderated owing to base effect. Agency channel contributed 81% of overall business
- Star Premier and Women's Care launched in previous quarter are doing well
- Average rise in sum insured per policy is 19% YoY to ₹1.8 lakh
- In Star Medi-classic product, the company has taken 25% price hike, it contributed 6% to total retail premium
- Entered into banca tied up with IDFC First Bank for distribution on products
- Current quarter claim ratio has 0.7% impact due to Covid claims. Claim expense higher by ~2% due to Covid related precautions and test
- Lower scale of premium (1st quarter phenomenon) has led to slight increase in opex ratio. In Q2FY22, ~2% of opex was shifted in claims to factor in cost related to in-house claim settlement. Thus, opex ratio to normalize from Q2FY23 onwards
- Guidance for claims ratio is 63-65% and combined ratio at 93-95% in FY23E
- Premium retail growth to be ~20-25%, overall growth could be slightly lower due to group business.
- Solvency to improve owing to shift from existing claim basis to premium basis. Solvency to be \sim 193-198% by year end
- ESOP expenses ₹55 crore in Q1FY23. Total impact to be ~₹145 crore in FY23E (₹55 crore in Q2FY23 and ₹35 crore in Q3FY23)
- Star Health, only SAHI player on government healthcare platform. Expect healthy traction ahead, though clarity on benefits awaited
- ~8% of premium is contributed by pure online channel

Peer comparison

Exhibit 3: Peer C	omparis	on																		
Sector / Company	CMP			M Cap EPS (₹)			P/E (x)			P/EV (x)			RoE (%)							
Sector / Company	(र)	TP(₹)	Rating	(₹ bn)	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E
SBI Life Insurance	1295	1500	Buy	1145	14.6	15.1	17.6	21.5	88.9	86.0	73.7	60.2	3.9	3.3	2.9	2.5	15.2	8.5	12.0	14.0
HDFC Life	555	635	Buy	1204	6.7	5.7	7.4	8.9	82.5	97.1	75.0	62.4	4.2	3.9	3.1	2.5	17.6	18.0	18.1	18.2
Star Health	740	860	Buy	427	-15.1	-21.0	12.2	14.4	-49.1	-35.2	60.4	51.2	12.5	10.0	8.4	6.8	-23.6	-27.8	13.4	13.0
ICICI Lombard	1219	1550	Buy	609	32.4	25.9	21.3	19.3	37.6	47.1	57.2	63.2	7.5	6.6	5.7	5.0	21.3	14.5	14.8	15.1

Source: Company, ICICI Direct Research

🜈 Result update | ICICI Lombard General Insurance Company

ICICI Direct Research

Exhibit 4: Variance Analysis							
Policyholder's Account	Q1FY23	Q1FY23E	Q1FY22	YoY%	Q4FY22	000%	
Gross Premium Written	2463.7	2949.9	2185.1	12.7	3689.2	(33.2)	Largely driven by 20.2% YoY uptick in retail health
(-) Reinsurance ceded	119.6	177.0	135.5	(11.8)	215.4	(44.5)	
Net written premium (NWP)	2344.1	2772.9	2049.6	14.4	3473.8	(32.5)	
Net earned premium (NEP)	2687.1	2628.6	2243.0	19.8	2621.2	2.5	Higher unwinding of URR fuels NEP growth
(-) Net Incurred Claims	1781.1	1856.2	2041.4	(12.8)	1784.8	(0.2)	Claims fall steeply as impact of Covid subsides
(-) Net Commission Expense	322.0	310.9	266.5	20.8	507.2	(36.5)	
(-) Operating expenses related to insurance business	427.2	415.2	351.0	21.7	546.4	(21.8)	
(-) Total expense	2530.3	2582.4	2659.0	(4.8)	2838.4	(10.9)	
Underwriting Profit/Loss	156.8	46.3	(416.0)	(137.7)	(217.2)	(172.2)	Combined ratio declines at 98.2% vs 121% YoY
Investment Income	122.0	150.0	88.9	37.2	119.2	2.3	
Operating Profit/Loss	278.8	196.3	(327.1)	(185.2)	(98.0)	(384.4)	
Transfer to Shareholder's Account	278.8	196.3	(327.1)	(185.2)	(98.0)	(384.4)	

Shareholder's Account	Q1FY23	Q1FY23E	Q1FY22	YoY%	Q4FY22	000%	
Operating Profit/Loss	278.8	196.3	(327.1)	(185.2)	(98.0)	(384.4)	
Investment Income	82.1	60.0	55.7	47.3	60.6	35.3	Rise in investment income despite rise in interest rate scenario
Other Income	1.8	0.0	0.0	4213.7	1.17	50.4	
(-) Expense and Provision	74.7	80.0	9.0	730.1	79.5	(6.1)	
Profit before tax	287.9	176.3	(280.3)	(202.7)	(115.7)	(348.8)	
(-) Provision for Taxation	74.7	33.8	(70.5)	(206.0)	(33.7)	(321.6)	
Profit after Tax	213.2	142.6	(209.8)	(201.6)	(82.0)	(359.9)	Net profit as lower claims drive performance

Source: Company, ICICI Direct Research

Exhibit 5: Change in estimates

		FY23E		FY24E				
	Old	New	% change	Old	New	% change		
Gross written premium (GWP)	14847.0	14356.8	-3.3%	18564.0	17664.0	-4.8%		
Net earned premium (NEP)	12641.6	12298.4	-2.7%	15311.5	14735.9	-3.8%		
Net Incurred Claims	8659.5	8239.9	-4.8%	10335.3	9946.7	-3.8%		
Underwriting Profit/Loss	162.6	326.1	100.6%	426.8	395.9	-7.3%		
Operating Profit/Loss	685.0	848.5	23.9%	1050.9	1019.0	-3.0%		
Profit after Tax	632.6	705.4	11.5%	889.6	832.2	-6.5%		

Source: Company, ICICI Direct Research

Exhibit 6: Assumption

Exhibit 0. Assumption				
	Curren	t	Earlier	•
	FY23E	FY24E	FY23E	FY24E
NWP growth (%)	21.0	23.0	25.1	25.0
NEP growth (%)	24.0	19.8	27.5	21.1
Claims ratio (%)	67.0	67.5	68.5	67.5
Commission ratio (%)	12.7	12.5	12.4	12.1
Expenses ratio (%)	16.1	15.2	15.6	14.9
Combined ratio (%)	95.8	95.2	96.5	94.5
Underwriting Profit (%)	1.5	1.3	0.7	1.8
EBIT/NEP (%)	7.9	7.8	6.9	8.0

Source: Company, ICICI Direct Research

Financial summary

Exhibit 44: Policy holder's	Accour	nt		:	₹ crore
Policyholder's Account	FY20	FY21	FY22	FY23E	FY24E
Gross written premium (GWP)	6890.7	9388.5	11739.6	14356.8	17664.0
(-) Reinsurance ceded	1629.3	2204.2	704.4	1005.0	1236.5
Net written premium (NWP)	5261.4	7144.8	11035.2	13351.8	16427.5
Net earned premium (NEP)	4693.0	5022.8	9917.7	12298.4	14735.9
(-) Net Incurred Claims	3087.4	4369.5	8727.5	8239.9	9946.7
(-) Net Commission Expense	340.9	583.8	1467.7	1695.7	2053.4
(-) Operating expense	1102.0	1401.4	1849.6	2036.7	2339.9
(-) Other expense	(5.8)	0.0	0.0	0.0	0.0
(-) Total expense	4524.5	6354.6	12044.8	11972.3	14340.0
Underwriting Profit/Loss	168.4	(1331.8)	(2127.2)	326.1	395.9
Investment Income	192.4	260.6	420.6	522.4	623.1
Operating Profit/Loss	360.8	(1071.2)	(1706.6)	848.5	1019.0
Transfer to Shareholder's Account	360.8	(1071.2)	(1706.6)	848.5	1019.0

Exhibit 45: Shareholder's A	ccoun	t		Ę	crore
Shareholder's Account	FY20	FY21	FY22E	FY23E	FY24E
Operating Profit (from Policyholer's &	360.8	(1071.2)	(1706.6)	848.5	1019.0
Investment Income	101.1	163.1	226.5	281.3	335.5
Other Income	0.0	0.3	0.3	0.4	0.4
(-) Expense and Provision	48.6	138.2	128.7	187.5	242.8
Profit before tax	413.4	(1046.0)	(1608.4)	942.6	1112.1
Provision for Taxation	(141.4)	220.4	404.8	(237.3)	(279.9)
Profit after Tax	272.0	(825.6)	(1203.6)	705.4	832.2

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

					₹ crore
Balance Sheet	FY20	FY21	FY22E	FY23E	FY24E
Source of Funds					
Share Capital	490.6	548.1	572.9	575.9	575.9
Reserves and Surplus	1157.1	3675.8	5674.5	5668.5	5793.6
Net Worth	1647.7	4223.9	6247.4	6244.4	6369.5
Fair value gains	3.1	(7.6)	0.7	17.1	36.6
Borrowings	250.0	250.0	750.0	800.0	850.0
Deferred Tax Liability	0.0	0.0	0.0	0.0	0.0
Total	1900.8	4466.6	6998.0	7061.4	7256.1
Application of Funds					
Shareholder Investments	1478.2	2632.1	3675.1	4252.3	5297.2
Policyholder Investments	2811.7	4204.6	6825.3	7897.1	9837.7
Total Investments	4290.0	6836.7	10500.4	12149.4	15135.0
Deferred Tax Assets	146.7	421.3	826.1	588.9	309.0
Fixed Assets	101.9	99.0	125.1	187.1	275.4
Cash and Bank balance	611.4	1879.0	1090.9	1352.8	1620.9
Other current assets	976.7	1265.0	682.7	889.5	1020.3
Total Current Assets	1588.2	3144.0	1773.6	2242.4	2641.3
Current Liabilities	1179.4	1564.3	1839.1	1722.2	2047.3
Provision	3050.6	5194.6	6312.2	7365.6	9057.2
Total Current Liabilities	4230.0	6758.9	8151.3	9087.8	11104.5
Net Current Assets	(2641.8)	(3614.9)	(6377.7)	(6845.5)	(8463.2)
Total	1900.8	4466.6	6998.0	7061.4	7256.1

Exhibit 47: Key Ratios					
Key Ratios	FY20	FY21	FY22E	FY23E	FY24E
Incurred Claims ratio (%)	65.8	87.0	88.0	68.5	67.5
Commission Ratio (%)	6.5	8.2	13.3	12.4	12.1
Expense Ratio (%)	21.4	20.7	17.3	15.6	14.9
Combined ratio (%)	93.7	115.9	118.6	96.5	94.5
Investment yield (%)	8.1	7.4	9.6	8.0	8.2
Investment Income / NEP (%)	6.5	7.8	6.4	6.3	6.2
PAT margin (%)	5.8	(16.4)	(12.1)	5.0	5.8
RoE (%)	16.5	(23.6)	(27.8)	12.2	13.9
ROCE (%)	14.3	(22.0)	(23.7)	10.6	12.3
NWP/Net Worth (x)	3.2	1.7	1.8	2.2	2.7
Debt/EBIT (x)	0.6	(0.2)	(0.5)	0.9	0.7
Debt/Equity (x)	0.15	0.06	0.12	0.13	0.13
ABV (₹)	28.1	59.6	73.7	87.9	108.2
Valuation					
Price/Float (x)	0.9	0.6	0.4	0.3	0.3
P/GWP (x)	0.6	0.4	0.3	0.3	0.2
P/E (x)	151.5	(49.9)	(34.3)	65.5	46.6
P/ABV (x)	25.0	11.8	9.5	8.0	6.5

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Kajal Gandhi, CA, Vishal Narnolia, MBA and Sameer Sawant, MBA and Pravin Mule, MBA, Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities form doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be bubject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.